Brian David Dynlacht

Brian David Dynlacht (born September 3, 1965 in Brooklyn, New York ), is a Jewish-American biochemist and Professor in the Department of Pathology of New York University School of Medicine. In 2002, Dynlacht reported the discovery of CCP110, which is now thought to be at the center of a molecular switch governing the centriole to ciliary transition in mammalian cells.

Brian David Dynlacht is the middle child of 3 children born to Sigmund (Zdzislaw) Dynlacht of Warsaw, Poland and Janice Deutsch Dynlacht of Brooklyn, New York.

Dynlacht earned a Bachelor of Science in 1987 from Yale University, where he first conducted research under the mentorship of Paul Howard-Flanders. He was awarded a PhD in Biochemistry in 1992 from the University of California at Berkeley. As a graduate student with Robert Tjian, Dynlacht and Timothy Hoey first discovered and functionally characterized TFIID. Dynlacht carried out postdoctoral studies with Ed Harlow at the Massachusetts General Hospital, where he definitively proved for the first time, in vitro using purified proteins, the biochemical mechanism through which transcription can be directly repressed by the Rb tumor suppressor protein. This study also provided the first example of an in vitro transcription system that responds to regulatory events acting upstream of the binding of a transactivator.

Dynlacht was appointed to the position of Assistant professor in the Department of Molecular and Cellular Biology at Harvard University in 1995 and then associate professor in 1999. He is currently a Professor in Pathology in the Laura and Isaac Perlmutter Cancer Center of the New York University School of Medicine.

Dynlacht’s research has been recognized by a Presidential Early Career Award for Scientists and Engineers in 1998. He has also received numerous career awards including Kenneth G. and Elaine A. Langone Damon Runyon Scholar Award (1996), Pew Scholar in the Biomedical Sciences (1998) and the Irma T. Hirchl Trust Career Award (2005).

...
Wikipedia